Summary Slide.png (120.11 kB)

24-hour Serial Spirometric Assessment of Once-Daily Fluticasone furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study

figure

posted on 28.09.2020, 10:22 by David A Lipson, Ruby Birk, Noushin Brealey, Chang-Qing Zhu

The above Summary Slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

Funding

GlaxoSmithKline

History

References

https://link.springer.com/article/10.1007/s12325-020-01496-7

Usage metrics

Read the peer-reviewed publication

24-hour Serial Spirometric Assessment of Once-Daily Fluticasone furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study

Advances in Therapy

Keywords

Chronic obstructive pulmonary disease Lung function Single-inhaler triple therapy Long-acting β2-agonist Long-acting muscarinic antagonist Inhaled corticosteroid Serial FEV1

Licence

CC BY-NC 4.0

24-hour Serial Spirometric Assessment of Once-Daily Fluticasone furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study

Funding

GlaxoSmithKline

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports